

Anthony Joshua

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/76307/anthony-joshua-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114
papers

11,464
citations

36
h-index

107
g-index

125
ext. papers

14,064
ext. citations

7.7
avg, IF

5.62
L-index

#	Paper	IF	Citations
114	Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.. <i>BMC Medicine</i> , 2022 , 20, 112	11.4	1
113	Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. <i>Cancer Research Communications</i> , 2022 , 2, 293-306		0
112	A review of the cutaneous toxicities of tebentafusp-Featuring two cases involving superficial bullous reactions.. <i>Australasian Journal of Dermatology</i> , 2022 ,	1.3	0
111	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100941	2.2	7
110	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. <i>EBioMedicine</i> , 2021 , 72, 103625	8.8	5
109	Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
108	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021 , 127, 2587-2594	6.4	4
107	UpFrontPSMA: a randomized phase 2 study of sequential Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). <i>BJU International</i> , 2021 , 128, 331-342	5.6	13
106	To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma. <i>Cancer</i> , 2021 , 127, 2333-2341	6.4	0
105	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. <i>Genome Medicine</i> , 2021 , 13, 81	14.4	6
104	Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9527-9527	2.2	4
103	Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 1007-1027	6.2	3
102	Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	4
101	Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report. <i>Annals of Oncology</i> , 2021 , 32, 280-282	10.3	3
100	Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021 , 79, 177-179	10.2	0
99	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021 , 144, 182-191	7.5	23
98	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. <i>Clinical Cancer Research</i> , 2021 , 27, 2340-2351	12.9	4

97	[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021 , 397, 797-804	40	161
96	ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). <i>BJU International</i> , 2021 , 128, 642-651	5.6	2
95	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021 , 385, 1196-1206	59.2	63
94	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021 , 80, 275-279	10.2	3
93	PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?. <i>Cancers</i> , 2021 , 13,	6.6	2
92	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021 , 157, 391-402	7.5	2
91	Oncology in 2050 - A Retrospective?. <i>Oncologist</i> , 2020 , 25, e1127-e1130	5.7	1
90	TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5500-5500	2.2	42
89	The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. <i>Cancers</i> , 2020 , 12,	6.6	5
88	Fats and Mets, KRAS-Driven Lipid Dysregulation Affects Metastatic Potential in Pancreatic Cancer. <i>Cancer Research</i> , 2020 , 80, 4886-4887	10.1	3
87	Phase I/II Trial of the Combination of Lutetium Prostate specific Membrane Antigen 617 and Idroneoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). <i>European Urology Oncology</i> , 2020 , 4, 963-963	6.7	14
86	Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. <i>Epigenomics</i> , 2020 , 12, 1317-1332	4.4	6
85	Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies. <i>Hormones and Cancer</i> , 2020 , 11, 155-169	5	9
84	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). <i>BMJ Open</i> , 2020 , 10, e033667	3	5
83	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. <i>Annals of Oncology</i> , 2019 , 30, 582-588	10.3	325
82	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 121-131	59.2	479
81	Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. <i>Annals of Oncology</i> , 2019 , 30, 1370-1380	10.3	74
80	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. <i>British Journal of Cancer</i> , 2019 , 120, 1113-1119	8.7	42

79	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019 , 24, 1188-1194	5.7	17
78	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 773-785	7.4	53
77	Health status, emergency department visits, and oncologists' feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 169-174	3.6	3
76	Developing a pan-cancer research autopsy programme. <i>Journal of Clinical Pathology</i> , 2019 , 72, 689-695	3.9	3
75	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz071	4.6	2
74	Therapeutic implications of germline genetic findings in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 386-396	19.4	24
73	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019 , 125, 1341-1349	6.4	78
72	Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019 , 15 Suppl 10, 3-10	1.9	3
71	Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. <i>European Journal of Cancer</i> , 2019 , 107, 1-7	7.5	24
70	Results of a Prospective Phase 2 Pilot Trial of Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 15-22	3.3	93
69	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 240.e13-240.e20	2.8	6
68	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018 , 24, 4960-4967	12.9	142
67	A randomized phase II trial of geriatric assessment and management for older cancer patients. <i>Supportive Care in Cancer</i> , 2018 , 26, 109-117	3.9	20
66	Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer. <i>Future Science OA</i> , 2018 , 4, FSO253	2.7	5
65	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). <i>Journal of Clinical Oncology</i> , 2018 , 36, 1232-1239	2.2	135
64	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018 , 104, 137-144	7.5	63
63	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 439-445	4.9	6
62	Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 959-969	3.5	26

61	Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS). <i>PLoS ONE</i> , 2017 , 12, e0170544	3.7	9
60	AR Signaling and the PI3K Pathway in Prostate Cancer. <i>Cancers</i> , 2017 , 9,	6.6	82
59	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016 , 8, 109	14.4	149
58	Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. <i>Journal of Translational Medicine</i> , 2016 , 14, 12	8.5	15
57	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1510-7	2.2	509
56	A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. <i>Annals of Oncology</i> , 2016 , 27, 454-60	10.3	107
55	A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone. <i>Journal of Geriatric Oncology</i> , 2016 , 7, 81-9	3.6	18
54	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1600-9	27.4	666
53	Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. <i>Oncology Letters</i> , 2016 , 11, 1581-1585	2.6	29
52	Non-melanoma Skin Cancer 2016 , 225-232		
51	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016 , 115, 1186-1192	8.7	33
50	Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. <i>British Journal of Cancer</i> , 2015 , 112, 832-40	8.7	37
49	Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. <i>Annals of Oncology</i> , 2015 , 26, 2044-53	15.3	69
48	Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e229-e233	3.3	32
47	Pembrolizumab 2015 , 3, 36		131
46	Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. <i>European Urology</i> , 2015 , 67, 441-7	10.2	31
45	A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 124-9	3.3	9
44	A phase 2 study of tremelimumab in patients with advanced uveal melanoma. <i>Melanoma Research</i> , 2015 , 25, 342-7	3.3	59

43	Increased treatment-related toxicity subsequent to an anti-PD-1 agent. <i>Current Oncology</i> , 2015 , 22, e320-8	2.8	5
42	Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. <i>Clinical Cancer Research</i> , 2015 , 21, 1621-7	12.9	46
41	Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 23-8	3.6	20
40	IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 279-279	2.2	2
39	A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2014 , 74, 1544-50	4.2	40
38	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , 2014 , 384, 1109-17	40	1340
37	Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. <i>European Journal of Cancer</i> , 2014 , 50, 2399-407	7.5	11
36	Enzalutamide in metastatic prostate cancer before chemotherapy. <i>New England Journal of Medicine</i> , 2014 , 371, 424-33	59.2	1892
35	Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC) 2014 , 2,		6
34	Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review. <i>Endocrine Practice</i> , 2014 , 20, e145-50	3.2	11
33	Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma 2014 , 2, 41		70
32	New treatments for metastatic melanoma. <i>Cmaj</i> , 2014 , 186, 754-60	3.5	9
31	Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2397-405	27.4	285
30	Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome 2014 ,		19
29	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3000-3000	2.2	9
28	Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3005-3005	2.2	47
27	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3015-3015	2.2	17
26	Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5007-5007	2.2	2

25	Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5051-5051	2.2	2
24	Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5077-5077	2.2	1
23	Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5078-5078	2.2	1
22	Do special access programs facilitate off-label prescribing? The experience of enzalutamide in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6550-6550	2.2	1
21	Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16045-e16045	2.2	3
20	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA9000-LBA9000	2.2	18
19	A single-arm, phase II, multicenter trial of sunitinib (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Updated interim results.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15621-e15621	2.2	
18	PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. <i>Modern Pathology</i> , 2013 , 26, 435-47	9.8	62
17	Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: a pilot project at a Canadian cancer center. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 342-345.e1	3.3	1
16	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>New England Journal of Medicine</i> , 2013 , 369, 134-44	59.2	2661
15	Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. <i>Annals of Oncology</i> , 2013 , 24, 2972-7	10.3	97
14	Prostate cancer as a model system for genetic diversity in tumors. <i>Advances in Cancer Research</i> , 2011 , 112, 183-216	5.9	23
13	Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. <i>Prostate</i> , 2011 , 71, 778-90	4.2	16
12	Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. <i>Anti-Cancer Drugs</i> , 2010 , 21, 206-9	2.4	27
11	Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 5-9	5.6	128
10	Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. <i>Modern Pathology</i> , 2008 , 21, 1451-60	9.8	235
9	Prostatic preneoplasia and beyond. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2008 , 1785, 156-81	11.2	15
8	Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. <i>Cancer Genetics and Cytogenetics</i> , 2006 , 169, 128-37		139

7	Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. <i>Neoplasia</i> , 2006 , 8, 465-9	6.4	149
6	Smoking reduction does work: resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years. <i>Respirology</i> , 2005 , 10, 233-8	3.6	7
5	Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. <i>Internal Medicine Journal</i> , 2005 , 35, 468-72	1.6	11
4	Small blue cell tumors of the rectum. Case 2. Small-cell carcinoma of the rectum. <i>Journal of Clinical Oncology</i> , 2005 , 23, 912-3	2.2	12
3	The use of taxanes in choriocarcinoma; a case report and review of the literature. <i>Gynecologic Oncology</i> , 2004 , 94, 581-3	4.9	5
2	Reliable method of isolating transfected clones from the LNCaP human prostatic cell line. <i>BioTechniques</i> , 1997 , 23, 66, 68, 70	2.5	5
1	Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor. <i>Skin Health and Disease</i> , e71		